Cargando…
Hematopoietic SCT in Europe: data and trends in 2011
In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42%), 18 605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32% 94% allogeneic); lymphoid neoplasias; non-Hodgkin's lymphoma, Hodgkin...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763517/ https://www.ncbi.nlm.nih.gov/pubmed/23584439 http://dx.doi.org/10.1038/bmt.2013.51 |
_version_ | 1782283026412077056 |
---|---|
author | Passweg, J R Baldomero, H Bregni, M Cesaro, S Dreger, P Duarte, R F Falkenburg, J H F Kröger, N Farge-Bancel, D Bobby Gaspar, H Marsh, J Mohty, M Peters, C Sureda, A Velardi, A Ruiz de Elvira, C Madrigal, A |
author_facet | Passweg, J R Baldomero, H Bregni, M Cesaro, S Dreger, P Duarte, R F Falkenburg, J H F Kröger, N Farge-Bancel, D Bobby Gaspar, H Marsh, J Mohty, M Peters, C Sureda, A Velardi, A Ruiz de Elvira, C Madrigal, A |
author_sort | Passweg, J R |
collection | PubMed |
description | In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42%), 18 605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32% 94% allogeneic); lymphoid neoplasias; non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasma cell disorders; 18 433 (57% 12% allogeneic); solid tumours; 1573 (5% 5% allogeneic); and non-malignant disorders; 1830 (6% 92% allogeneic). There were more unrelated donors than HLA identical sibling donors (54% versus 39%); proportion of peripheral blood as stem cell source was 99% for autologous and 73% for allogeneic HSCT. Cord blood was only used in allogeneic transplants (6% of total). In the past 10 years, the overall number of transplants has increased by 53%. Allogeneic HSCT have doubled (from 7272 to 14 549) while, autologous have increased by 32% and continue to increase by about 1100 HSCT per year since 2001. In the past 2 years, an increase of >2000 HSCT per year was seen. Transplant activity is shown by team size. For allogeneic HSCT, we show use of reduced-intensity conditioning versus myeloablative conditioning across Europe and use of post-transplant donor lymphocyte infusions with considerable variation across different countries. |
format | Online Article Text |
id | pubmed-3763517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-37635172013-09-09 Hematopoietic SCT in Europe: data and trends in 2011 Passweg, J R Baldomero, H Bregni, M Cesaro, S Dreger, P Duarte, R F Falkenburg, J H F Kröger, N Farge-Bancel, D Bobby Gaspar, H Marsh, J Mohty, M Peters, C Sureda, A Velardi, A Ruiz de Elvira, C Madrigal, A Bone Marrow Transplant Special Report In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42%), 18 605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32% 94% allogeneic); lymphoid neoplasias; non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasma cell disorders; 18 433 (57% 12% allogeneic); solid tumours; 1573 (5% 5% allogeneic); and non-malignant disorders; 1830 (6% 92% allogeneic). There were more unrelated donors than HLA identical sibling donors (54% versus 39%); proportion of peripheral blood as stem cell source was 99% for autologous and 73% for allogeneic HSCT. Cord blood was only used in allogeneic transplants (6% of total). In the past 10 years, the overall number of transplants has increased by 53%. Allogeneic HSCT have doubled (from 7272 to 14 549) while, autologous have increased by 32% and continue to increase by about 1100 HSCT per year since 2001. In the past 2 years, an increase of >2000 HSCT per year was seen. Transplant activity is shown by team size. For allogeneic HSCT, we show use of reduced-intensity conditioning versus myeloablative conditioning across Europe and use of post-transplant donor lymphocyte infusions with considerable variation across different countries. Nature Publishing Group 2013-09 2013-04-15 /pmc/articles/PMC3763517/ /pubmed/23584439 http://dx.doi.org/10.1038/bmt.2013.51 Text en Copyright © 2013 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Special Report Passweg, J R Baldomero, H Bregni, M Cesaro, S Dreger, P Duarte, R F Falkenburg, J H F Kröger, N Farge-Bancel, D Bobby Gaspar, H Marsh, J Mohty, M Peters, C Sureda, A Velardi, A Ruiz de Elvira, C Madrigal, A Hematopoietic SCT in Europe: data and trends in 2011 |
title | Hematopoietic SCT in Europe: data and trends in 2011 |
title_full | Hematopoietic SCT in Europe: data and trends in 2011 |
title_fullStr | Hematopoietic SCT in Europe: data and trends in 2011 |
title_full_unstemmed | Hematopoietic SCT in Europe: data and trends in 2011 |
title_short | Hematopoietic SCT in Europe: data and trends in 2011 |
title_sort | hematopoietic sct in europe: data and trends in 2011 |
topic | Special Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763517/ https://www.ncbi.nlm.nih.gov/pubmed/23584439 http://dx.doi.org/10.1038/bmt.2013.51 |
work_keys_str_mv | AT passwegjr hematopoieticsctineuropedataandtrendsin2011 AT baldomeroh hematopoieticsctineuropedataandtrendsin2011 AT bregnim hematopoieticsctineuropedataandtrendsin2011 AT cesaros hematopoieticsctineuropedataandtrendsin2011 AT dregerp hematopoieticsctineuropedataandtrendsin2011 AT duarterf hematopoieticsctineuropedataandtrendsin2011 AT falkenburgjhf hematopoieticsctineuropedataandtrendsin2011 AT krogern hematopoieticsctineuropedataandtrendsin2011 AT fargebanceld hematopoieticsctineuropedataandtrendsin2011 AT bobbygasparh hematopoieticsctineuropedataandtrendsin2011 AT marshj hematopoieticsctineuropedataandtrendsin2011 AT mohtym hematopoieticsctineuropedataandtrendsin2011 AT petersc hematopoieticsctineuropedataandtrendsin2011 AT suredaa hematopoieticsctineuropedataandtrendsin2011 AT velardia hematopoieticsctineuropedataandtrendsin2011 AT ruizdeelvirac hematopoieticsctineuropedataandtrendsin2011 AT madrigala hematopoieticsctineuropedataandtrendsin2011 |